FDA

Patient with type 1 diabetes
#FDA #Sanofi #Type 1 diabetes

FDA expedites review of Sanofi’s Type 1 diabetes drug

The US Food and Drug Administration (FDA) has accepted Sanofi’s Stage 3 Type 1 diabetes drug, Tzield, for expedited review.  Tzield delays the progression of Stage 3 Type 1 diabetes (T1D) in patients eight years or older who have recently been diagnosed. Sanofi’s drug received expedited review… Read More

#News #Regulatory

Respiratory system
#FDA #Idiopathic pulmonary fibrosis

FDA approves nerandomilast tablets to treat IPF

The US Food and Drug Administration (FDA) has approved Boehringer’s Jascayd (nerandomilast) tablets to treat idiopathic pulmonary fibrosis (IPF).  Jascayd is an oral treatment option for adult patients with IPF, becoming the first and only preferential inhibitor of phosphodiesterase 4B (PDE4B)… Read More

#News #Regulatory

Screening patient for AMD
#AMD #Clinical trial #Complement Therapeutics #FDA #Gene therapy #Geographic atrophy #Ophthalmology

FDA clears gene therapy trial in geographic atrophy

The US Food and Drug Administration (FDA) has cleared Complement Therapeutics’ Investigational New Drug (IND) application for CTx001, the company’s lead gene therapy candidate.   The IND clearance enables initiation of the Opti-GAIN Phase I/II clinical trial in patients with geographic atrophy (GA) secondary to age-related macular degeneration… Read More

#News #Regulatory

FDA
#FDA #Orphan drugs

FDA grants Orphan Drug Designation to gMG treatment CNP-106

The US Food and Drug Administration (FDA) has granted orphan drug designation to CNP-106, an investigational therapy for the treatment of generalised myasthenia gravis (gMG).  CNP-106 is a biodegradable nanoparticle that encapsulates seven acetylcholine receptor (AChR) antigens. It is being evaluated for its potential to induce… Read More

#News #Regulatory

Breast cancer
#Breast cancer #Eli Lilly #FDA #Gene mutation #Oncology

FDA approves Inluriyo in ER+, HER2-, ESR1-mutated breast cancer

The US Food and Drug Administration (FDA) has approved Eli Lilly’s Inluriyo (imlunestrant, 200mg tablets), an oral oestrogen receptor antagonist.  It is approved for the treatment of adults with oestrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2–), ESR1-mutated advanced or metastatic breast cancer (MBC) whose… Read More

#News #Regulatory #Trending News

Dystrophin muscle protein
#FDA #Sanofi

FDA grants fast track designation to DM1 treatment SAR446268

The US Food and Drug Administration (FDA) has granted fast track designation to SAR446268 for the treatment of non-congenital DM1 myotonic dystrophy type 1 (DM1).  The announcement was made by pharmaceutical company Sanofi, who developed SAR446268 as a one-time gene therapy. Fast track designation will… Read More

#News

X-ray showing colon cancer
#Biopharma #Cancer #FDA

Alnodesertib granted fast track designation by the FDA

The ATR inhibitor alnodesertib has been granted fast track designation by the US Food and Drug Administration (FDA), biopharmaceutical company Artios Pharma Limited has announced.  Alnodesertib is a treatment for adult patients with ATM negative metastatic colorectal cancer (mCRC) in the third-line setting, in combination with a… Read More

#News

Laboratory research
#FDA

LP-10 could become first FDA-approved OLP treatment

Promising results from a clinical trial of LP-10 suggest the drug could become the first FDA-approved therapy for symptomatic oral lichen planus (OLP). LP-10, a proprietary liposomal tacrolimus oral rinse, was evaluated in a Phase IIa multicentre, dose-ranging clinical trial. Twenty-seven patients completed a four-week treatment course with… Read More

#News

Healthy cells
#CAR-T #Cell therapy #FDA #United States

FDA cracks down on overseas cell processing for clinical trials

The US Food and Drug Administration (FDA) has prohibited new clinical trials that send US patients’ live cells overseas, including to China, for gene editing and return infusion.   While the scope and impact are unclear, smaller cell and gene therapy companies that rely on foreign manufacturing may… Read More

#News

Eye
#Age-related diseases (ARDs) #AMD #Fast Track designation #FDA #Ophthalmology #Sanofi

FDA fast-tracks Sanofi’s AMD gene therapy

Sanofi’s investigational one-time intravitreal gene therapy for the treatment of neovascular age-related macular degeneration (AMD) has been granted fast track designation by the US Food and Drug Administration (FDA).   Sanofi’s SAR402663 is currently being evaluated in a Phase I/II clinical trial for patients with neovascular AMD. Read More

#News #Regulatory

FDA
#Autoimmune disease #Clinical trials #Drug approvals #FDA

FDA approves first BTK inhibitor for immune thrombocytopenia 

The US Food and Drug Administration (FDA) has approved Wayrilz (rilzabrutinib) for adults with persistent or chronic immune thrombocytopenia (ITP) who have had an insufficient response to a previous treatment.   The approval was based on the pivotal LUNA 3 Phase III study, in which Wayrilz met the… Read More

#News

#Drug discovery #European Medicines Agency #FDA #Health Canada #Regulatory

This week in drug discovery (25-29 August) 

News round-up for 25-29 August by DDW Senior Digital Content Editor Diana Turner. There have been some significant regulatory decisions this week, including a new orphan designation from the EMA and the FDA go-ahead for Rocket Pharma’s paused gene therapy trial. The top stories:… Read More

#News

pulmonary arterial hypertension
#Cereno Scientific #Fast Track designation #FDA

Cereno Scientific granted FDA fast track designation for CS1

The US Food and Drug Administration (FDA) has granted Fast Track designation to Cereno Scientific’s lead programme, CS1, for the treatment of pulmonary arterial hypertension (PAH).  “The Fast Track designation for CS1 underscores the FDA’s recognition of its potential to address the significant unmet need in PAH,”… Read More

#News #Regulatory

#FDA #Gene therapy #Phase II trial #Rare disease #Rocket Pharmaceuticals

FDA lifts hold on Rocket Pharma’s Phase II trial of RP-A501

The US Food and Drug Administration (FDA) has lifted the clinical hold on Rocket Pharmaceuticals’ pivotal Phase II trial of RP-A501 for the treatment of Danon disease.  The hold was lifted in under three months and led to an increase in  Rocket’s stock value by 30%. … Read More

#News

FDA
#FDA #Mitochondria #PTC Therapeutics #Rare disease

FDA rejects PTC Therapeutics’ drug for Friedreich’s ataxia

The US Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) stating its decision not to recommend PTC Therapeutics’ vatiquinone for Friedreich’s ataxia (FA).  The FDA stated in the CRL that substantial evidence of efficacy was not demonstrated for vatiquinone and that an additional… Read More

#News #Regulatory